Cortical structural differences following repeated ayahuasca use hold molecular signatures DOI Creative Commons
Pablo Mallaroni, Natasha L. Mason, Lilian Kloft

et al.

Frontiers in Neuroscience, Journal Year: 2023, Volume and Issue: 17

Published: Oct. 5, 2023

Serotonergic psychedelics such as ayahuasca are reported to promote both structural and functional neural plasticity via partial 5-HT2A agonism. However, little is known about how these molecular mechanisms may extend repeated psychedelic administration in humans, let alone neuroanatomy. While early evidence suggests localised changes cortical thickness long-term users, it unknown findings be reflected by large-scale anatomical brain networks comprising cytoarchitecturally complex regions.Here, we examined the relationship between gene expression markers of action morphometric change following usage, using high-field 7 Tesla neuroimaging data derived from 24 members an ayahuasca-using church (Santo Daime) case-matched controls.Using a similarity network (MSN) analysis, use was associated with spatially distributed patterning differentiation sensorimotor areas de-differentiation transmodal areas. Cortical MSN remodelling found correlated dysregulation well broader set genes encoding target receptors pertinent ayahuasca's effects. Furthermore, associations were similarly interrelated altered specific transcriptional factors immediate previously identified preclinical assays relevant psychedelic-induced neuroplasticity.Taken together, provide preliminary that scale up macroscale level organisation vivo. Closer attention role transcriptomics structural-functional coupling help account for behavioural differences observed experienced users.

Language: Английский

Neuroplasticity and Psychedelics: A comprehensive examination of classic and non-classic compounds in pre and clinical models DOI Creative Commons

Claudio Agnorelli,

Meg J. Spriggs, Kate Godfrey

et al.

Neuroscience & Biobehavioral Reviews, Journal Year: 2025, Volume and Issue: 172, P. 106132 - 106132

Published: April 4, 2025

Language: Английский

Citations

2
The Implication of 5-HT Receptor Family Members in Aggression, Depression and Suicide: Similarity and Difference DOI Open Access

Н. К. Попова,

А. С. Цыбко,

В. С. Науменко

et al.

International Journal of Molecular Sciences, Journal Year: 2022, Volume and Issue: 23(15), P. 8814 - 8814

Published: Aug. 8, 2022

Being different multifactorial forms of psychopathology, aggression, depression and suicidal behavior, which is considered to be violent aggression directed against the self, have principal neurobiological links: preclinical clinical evidence associates depression, behavior with dysregulation in central serotonergic (5-HT) neurotransmission. The implication types 5-HT receptors genetic epigenetic mechanisms suicidality has been well recognized. In this review, we consider compare orchestra involved these severe psychopathologies. Specifically, it concentrates on role 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT3 5-HT7 underlying predisposition behavior. review provides converging lines that: (1) depression-related include those pro-depressive properties (5-HT2A, 5-HT7) as providing an antidepressant effect (5-HT1A, 5-HT2C subtypes). (2) Aggression-related are identical exception receptors. Activation attenuate aggressiveness, whereas agonists intensify aggressive

Language: Английский

Citations

51
Psychedelics and Neural Plasticity: Therapeutic Implications DOI Creative Commons
Steven F. Grieco, Eero Ċastrén, Gitte M. Knudsen

et al.

Journal of Neuroscience, Journal Year: 2022, Volume and Issue: 42(45), P. 8439 - 8449

Published: Nov. 9, 2022

Psychedelic drugs have reemerged as tools to treat several brain disorders. Cultural attitudes toward them are changing, and scientists once again investigating the neural mechanisms through which these impact function. The significance of this research direction is reflected by recent work, including work presented authors at 2022 meeting Society for Neuroscience. As 2022, there were hundreds clinical trials recruiting participants testing therapeutic effects psychedelics. Emerging evidence suggests that psychedelic may exert some their long-lasting inducing structural functional plasticity. Herein, basic attempting elucidate compounds showcased. Topics covered include receptor binding sites, psychedelics on gene expression, dendrites, microcircuitry brain-wide circuits. We describe unmet needs current state translation clinic psychedelics, well other unanswered neuroscience questions addressable with future studies.

Language: Английский

Citations

45
Mini-review: The neurobiology of treating substance use disorders with classical psychedelics DOI Creative Commons

Marvin M. Urban,

Moritz R. Stingl,

Marcus W. Meinhardt

et al.

Frontiers in Neuroscience, Journal Year: 2023, Volume and Issue: 17

Published: April 17, 2023

The potential of psychedelics to persistently treat substance use disorders is known since the 1960s. However, biological mechanisms responsible for their therapeutic effects have not yet been fully elucidated. While it that serotonergic hallucinogens induce changes in gene expression and neuroplasticity, particularly prefrontal regions, theories on how specifically this counteracts alterations occur neuronal circuitry throughout course addiction are largely unknown. This narrative mini-review endeavors synthesize well-established knowledge from research with findings regarding neurobiological give an overview underlie treatment classical hallucinogenic compounds point out gaps current understanding.

Language: Английский

Citations

42
Alleviating anxiety and taming trauma: Novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder DOI Creative Commons
Nicolas Singewald, Simone B. Sartori, Andreas Reif

et al.

Neuropharmacology, Journal Year: 2023, Volume and Issue: 226, P. 109418 - 109418

Published: Jan. 6, 2023

Psychiatric disorders associated with psychological trauma, stress and anxiety are a highly prevalent increasing cause of morbidity worldwide. Current therapeutic approaches, including medication, effective in alleviating symptoms posttraumatic disorder (PTSD), at least some individuals, but have unwanted side-effects do not resolve underlying pathophysiology. After period stagnation, there is renewed enthusiasm from public, academic commercial parties designing developing drug treatments for these disorders. Here, we aim to provide snapshot the current state this field that written neuropharmacologists, also practicing clinicians interested lay-reader. introducing currently available treatments, summarize recent/ongoing clinical assessment novel medicines PTSD, grouped according primary neurochemical targets their potential produce acute and/or enduring effects. The evaluation putative targeting monoamine (including psychedelics), GABA, glutamate, cannabinoid, cholinergic neuropeptide systems, amongst others, discussed. We emphasize importance clinically assessing new medications based on firm understanding neurobiology stemming rapid advances being made neuroscience. This includes harnessing neuroplasticity bring about lasting beneficial changes brain rather than – as many transient attenuation symptoms, exemplified by combining psychotropic/cognitive enhancing drugs psychotherapeutic approaches. conclude noting other emerging trends promising phase development.

Language: Английский

Citations

39
Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment DOI Creative Commons
Jenessa N. Johnston, Bashkim Kadriu, Josh Allen

et al.

Neuropharmacology, Journal Year: 2023, Volume and Issue: 226, P. 109422 - 109422

Published: Jan. 13, 2023

Language: Английский

Citations

35
Therapeutic mechanisms of psychedelics and entactogens DOI
Boris D. Heifets, David E. Olson

Neuropsychopharmacology, Journal Year: 2023, Volume and Issue: 49(1), P. 104 - 118

Published: July 24, 2023

Language: Английский

Citations

30
Psychedelics and sexual functioning: a mixed-methods study DOI Creative Commons
Tommaso Barba, Hannes Kettner, Caterina Radu

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: Feb. 7, 2024

Abstract Do psychedelics affect sexual functioning postacutely? Anecdotal and qualitative evidence suggests they do, but this has never been formally tested. While satisfaction are generally regarded as an important aspect of human wellbeing, dysfunction is a common symptom mental health disorders. It also side effect selective serotonin reuptake inhibitors (SSRIs), first line treatment for depression. The aim the present paper was to investigate post-acute effects on self-reported functioning, combining data from two independent studies, one large naturalistic other smaller controlled clinical trial. Naturalistic use associated with improvements in several facets satisfaction, including improved pleasure communication during sex, one’s partner physical appearance. Convergent results were found trial psilocybin therapy versus SSRI, escitalopram, In trial, patients treated reported positive changes after treatment, while escitalopram did not. Despite focusing different populations settings, research study quantitively functioning. Results imply potential highlight need more this.

Language: Английский

Citations

9
Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects DOI Creative Commons
Drummond E-Wen McCulloch, Matthias E. Liechti, Kim P. C. Kuypers

et al.

Neuroscience Applied, Journal Year: 2024, Volume and Issue: 3, P. 103938 - 103938

Published: Jan. 1, 2024

Psychedelic drugs including psilocybin and LSD are undergoing clinical trials for a range of psychiatric neurological conditions, have particularly shown substantial promise in phase 2 studies depression. In this article we outline key knowledge gaps that may be imperative successful implementation psychedelic as medicines identified by members the European College Neuropsychopharmacology at New Frontiers Meeting Nice (2023). Key themes include pharmacokinetic pharmacodynamic characterisation, comparisons between psychedelics, relation duration subjective effects therapeutic outcomes, polypharmacology, impact psychological support. We conclude with perspective from Medicines Agency Heath Technology Assessors on most pressing requirements medical Europe.

Language: Английский

Citations

5
A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics DOI Creative Commons
Blerida Banushi, Vince Polito

Biology, Journal Year: 2023, Volume and Issue: 12(11), P. 1380 - 1380

Published: Oct. 28, 2023

Psychedelic substances have gained significant attention in recent years for their potential therapeutic effects on various psychiatric disorders. This review delves into the intricate cellular neurobiology of psychedelics, emphasizing applications addressing global burden mental illness. It focuses contemporary research pharmacological and molecular mechanisms underlying these substances, particularly role 5-HT2A receptor signaling promotion plasticity through TrkB-BDNF pathway. The also discusses how psychedelics affect receptors pathways explores as anti-inflammatory agents. Overall, this represents a development biomedical sciences with to transform health treatments.

Language: Английский

Citations

13